Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

How does Lonsurf work for metastatic CRC?

See the DrugPatentWatch profile for Lonsurf

How does Lonsurf (trifluridine/tipiracil) work in metastatic colorectal cancer (mCRC)?

Lonsurf is a chemotherapy medicine made from two components that work together to reduce DNA synthesis in rapidly dividing cancer cells:

- Trifluridine (FTD) is a nucleoside analog. After it enters cells, it is incorporated into DNA instead of normal nucleosides, which disrupts DNA processing and harms cancer-cell replication.
- Tipiracil helps trifluridine stay active by blocking thymidine breakdown. That inhibition raises the amount of usable trifluridine available to interfere with tumor DNA.

The net effect is damage to cancer-cell DNA and reduced ability of metastatic colorectal tumor cells to multiply.

What does that mean for tumor cells specifically?

In mCRC, tumor cells often rely on fast DNA replication. Lonsurf targets that dependency by:
- increasing the likelihood that DNA replication uses FTD incorrectly, and
- preventing rapid clearance of FTD through thymidine metabolism.

This creates replication stress and DNA dysfunction that limits tumor growth.

When is Lonsurf typically used in metastatic CRC?

Lonsurf is used for metastatic CRC in later treatment settings (after prior standard therapies). Exact lines of therapy can depend on local practice and patient history, but it is generally positioned after patients have already received other chemotherapy and targeted options when appropriate.

What patients often ask: is Lonsurf like 5-FU?

Lonsurf is different from classic fluoropyrimidines such as 5-FU or capecitabine. It can still cause effects linked to impaired DNA synthesis, but its mechanism is distinct because it relies on incorporation of a nucleoside analog (trifluridine) into DNA, helped by tipiracil’s inhibition of thymidine metabolism.

Where can I verify brand/patent and related background?

DrugPatentWatch.com tracks patents and exclusivity for oncology products and can be a useful starting point for corporate and regulatory background: https://www.drugpatentwatch.com/

Sources: (No external source content provided with the prompt, so no citations were used.)